Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E11.91 EPS (ttm)4.89 Insider Own0.80% Shs Outstand180.18M Perf Week-12.42%
Market Cap10.51B Forward P/E- EPS next Y-1.43 Insider Trans-35.31% Shs Float170.93M Perf Month-2.74%
Income902.70M PEG- EPS next Q-0.59 Inst Own94.40% Short Float9.16% Perf Quarter-0.17%
Sales1.37B P/S7.65 EPS this Y43.60% Inst Trans1.81% Short Ratio5.92 Perf Half Y-44.47%
Book/sh10.86 P/B5.37 EPS next Y-137.70% ROA92.60% Target Price89.38 Perf Year164.44%
Cash/sh10.12 P/C5.76 EPS next 5Y-7.30% ROE172.70% 52W Range21.11 - 111.36 Perf YTD-2.36%
Dividend- P/FCF11.51 EPS past 5Y16.20% ROI-18.10% 52W High-47.58% Beta2.37
Dividend %- Quick Ratio19.50 Sales past 5Y30.50% Gross Margin98.00% 52W Low176.55% ATR2.75
Employees509 Current Ratio19.70 Sales Q/Q3044.70% Oper. Margin67.80% RSI (14)40.88 Volatility5.31% 3.80%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin65.70% Rel Volume0.60 Prev Close58.31
ShortableYes LT Debt/Eq0.13 EarningsAug 08 AMC Payout0.00% Avg Volume2.65M Price58.38
Recom1.80 SMA20-9.06% SMA502.17% SMA200-18.81% Volume880,846 Change0.12%
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Sep-14-18 11:07AM  How Did Nektar Therapeuticss (NASDAQ:NKTR) 48.5% ROE Fare Against The Industry? Simply Wall St.
Sep-07-18 09:30AM  Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report? Zacks
Sep-06-18 02:25PM  Here's Why Nektar Therapeutics Jumped 26.4% in August Motley Fool
Sep-05-18 08:00AM  Today's Research Reports on Trending Tickers: Cronos Group and Nektar Therapeutics ACCESSWIRE
Aug-31-18 07:55AM  Market Trends Toward New Normal in Caesars Entertainment, Nektar Therapeutics, Boston Scientific, Apollo Commercial Real Estate Finance, Kellogg, and Foot Locker Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-24-18 02:00PM  3 Biotech Stocks That May Rise as Much as 16% Investopedia
09:30AM  Is Nektar Therapeutics (NKTR) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-21-18 11:45PM  Edited Transcript of NKTR earnings conference call or presentation 8-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-18 08:15AM  3 Big Stock Charts for Friday: Nektar Therapeutics, Waters and A.O. Smith InvestorPlace
Aug-09-18 09:52AM  Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y Zacks +6.09%
08:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Sangamo Therapeutics ACCESSWIRE
Aug-08-18 06:23PM  Nektar stock swings to after-hours loss following earnings beat MarketWatch
05:35PM  Nektar Therapeutics (NKTR) Q2 Earnings Meet Estimates Zacks
04:30PM  Nektar: 2Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018 PR Newswire
03:00PM  Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Aug-07-18 08:30AM  Why Nektar Therapeutics (NKTR) Might Surprise This Earnings Season Zacks
Aug-02-18 10:24AM  Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings? Zacks
Aug-01-18 05:24PM  The opioid drug that addicts don't like could be approved next spring American City Business Journals
05:00PM  Nektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets PR Newswire
02:27PM  Square Inc. expands Mid-Market headquarters office in one of San Francisco's biggest office leases this year American City Business Journals
Jul-30-18 09:15AM  Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA PR Newswire
Jul-26-18 11:11AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook Zacks
08:30AM  Investor Expectations to Drive Momentum within Fidelity Southern, Nektar Therapeutics, CSG Systems International, Ellington Financial, NBT, and Paylocity Holding Discovering Underlying Factors of Influence GlobeNewswire
Jul-13-18 09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
Jul-10-18 01:30PM  10 Beaten Down Stocks With Big Upside Investopedia
Jun-27-18 07:20AM  Free Technical Research on Nektar Therapeutics and Three More Biotech Equities ACCESSWIRE -7.15%
Jun-25-18 08:10AM  Today's Research Reports on Trending Tickers: Novavax and Nektar Therapeutics ACCESSWIRE
07:34AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Nektar Therapeutics for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-21-18 07:48AM  Is Nektar Therapeutics Still a Good Bet Despite the Correction? Investopedia
Jun-19-18 03:36PM  Nektar Is the One S&P 500 Company Without a Woman Director TheStreet.com
Jun-18-18 08:20AM  Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics ACCESSWIRE
Jun-14-18 10:00AM  New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting PR Newswire +5.50%
Jun-11-18 02:58PM  Former Incyte CEO Buys Slumping Nektar Shares Barrons.com
11:14AM  Biotech, Nektar Therapeutics Can't Handle Mondays Barrons.com
Jun-10-18 05:29PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-08-18 03:24AM  [$$] Are you following the wrong small-cap index? Financial Times
Jun-07-18 09:09PM  Why Nektar Therapeutics Stock Stumbled 11.8% Today Motley Fool -11.69%
06:34PM  After the Bell: 21 Out of 30 Dow Stocks Can't Be Wrong, Can They? Barrons.com
Jun-06-18 07:06PM  After the Bell: Dow Gains 346 Points and Didn't Need Tech to Do It Barrons.com +7.18%
04:32PM  Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today Motley Fool
04:15PM  Here's Why Nektar Therapeutics Jumped as Much as 17% Today Motley Fool
04:05PM  Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap Investor's Business Daily
08:54AM  Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5% Zacks
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 06:50PM  Cramer's lightning round: 'I beg you' to hold the stock of Hasbro CNBC +6.45%
01:50PM  Kohl's, Freeport McMoRan, Twitter, Nektar Therapeutics & ... CNBC Videos
12:59PM  Nektar's Sole Skeptic Warns of Parallels to Biggest Biotech Flop Bloomberg
11:00AM  Nektar Therapeutics Stock Is a Buy After a Major Market Misread InvestorPlace
09:46AM  Company News For Jun 5, 2018 Zacks
08:42AM  Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study Zacks
08:30AM  Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York PR Newswire
08:20AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Align Technology ACCESSWIRE
08:13AM  Do Nektars disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? MarketWatch
Jun-04-18 07:46PM  [$$] In Biotech, $6 Billion Can Vanish Quickly The Wall Street Journal -41.82%
05:14PM  Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug TheStreet.com
05:14PM  After the Bell: Dow Gains 178 Points as Risk Takes a Holiday Barrons.com
04:46PM  Merck and TJX climb; Nektar Therapeutics slumps Associated Press
04:40PM  Is Nektar Therapeutics Stock a Bargain Now? Motley Fool
04:31PM  Why Canadian Solar, Nektar Therapeutics, and Gulfport Energy Slumped Today Motley Fool
04:30PM  Nektars 42% Plunge Gives It a Record That No Company Wants Bloomberg
04:21PM  Here Are Winners And Losers From 2018's Biggest Cancer Drug Meeting Investor's Business Daily
04:01PM  Tech is the new capex, it's a cyclical play: Pro CNBC Videos
03:56PM  $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short CNBC
02:30PM  Why Bristol-Myers Squibb Company Shares Are Down Today InvestorPlace
01:49PM  [$$] Nektar's 39% Drop: A New Record for a Volatile Stock Barrons.com
01:45PM  Why Nektar Therapeutics Shares Are Plunging Today InvestorPlace
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
11:53AM  Nektar's 40% Plunge Is Compounded By Risky Cancer-Drug Bet Bloomberg
11:43AM  [$$] In Biotech, $6 Billion Can Vanish Quickly The Wall Street Journal
11:37AM  Nektar Roiled by Cancer Data, Other Biotechs Gain Barrons.com
09:39AM  Nektar shares drop 35% on 'underwhelming' cancer trial data MarketWatch
09:22AM  Morning Movers: Nektar Tumbles 28%, Facebook Falls, Whirlpool Rallies Barrons.com
09:14AM  Winners And Losers From Cancer Research's Biggest Event Forbes
08:35AM  Is the Options Market Predicting a Spike in Nektar (NKTR) Stock? Zacks
05:00AM  Nektar Plummets on Concerns Over Cancer-Drug Trial Results Bloomberg
Jun-03-18 09:49PM  Mixed results for Bristol/Nektar combination in cancer trial Reuters
02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
Jun-02-18 06:10PM  Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 PR Newswire
Jun-01-18 07:59PM  After the Bell: Dow's Payroll Rally Not Enough to Erase Wild Week's Losses Barrons.com +12.56%
04:32PM  Why Nektar Therapeutics, Ambac Financial Group, and Zuora Jumped Today Motley Fool
10:24AM  Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate Zacks
May-31-18 10:00PM  Can Nektar Therapeutics Disrupt This $20 Billion Market? Motley Fool
08:15AM  Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy PR Newswire
May-30-18 04:05PM  Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration PR Newswire
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-21-18 08:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Corcept Therapeutics ACCESSWIRE
May-18-18 05:03PM  After the Bell: Dow Ends Week Slightly in the Red Because Only Small Caps Rise in This Market Barrons.com +7.66%
04:51PM  Winners and Losers From the Biggest Cancer Meeting of the Year (So Far) Motley Fool
04:32PM  Why Dell Technologies, Nektar Therapeutics, and Westport Fuel Systems Jumped Today Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics ACCESSWIRE
May-17-18 05:34PM  After the Bell: Dow Drops 55 Points, Small-Caps Soar to a New High Barrons.com -7.66%
01:38PM  Here's Why Nektar Therapeutics Fell as Much as 11.1% Today Motley Fool
May-16-18 07:45PM  Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-15-18 02:28PM  Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace
06:33AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
May-14-18 09:44AM  Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y Zacks
May-11-18 09:56PM  Edited Transcript of NKTR earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
07:21AM  3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) InvestorPlace
May-10-18 04:24PM  Nektar: 1Q Earnings Snapshot Associated Press
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM
ROBIN HOWARD WPresident & CEOJun 27Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 27Sale47.3943,3332,053,551224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Sale49.3643,3332,138,917224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Option Exercise10.6943,334463,240267,690Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Sale51.8243,3342,245,568224,356Jun 27 07:42 PM
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale83.393,576298,20365,281May 18 07:07 PM
ROBIN HOWARD WPresident & CEOMay 16Sale83.3912,7911,066,641224,356May 18 07:06 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale83.394,917410,029162,596May 18 07:05 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale83.394,941412,03094,798May 18 07:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale83.394,060338,56376,201May 18 07:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale83.393,435286,44563,959May 18 07:01 PM
CHESS ROBERTDirectorMay 03Option Exercise8.7925,000219,700289,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 03Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Option Exercise10.6930,000320,700129,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 03Sale82.8643,3333,590,572237,147May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Sale82.8630,0002,485,80099,739May 03 08:43 PM
CHESS ROBERTDirectorMay 03Sale82.8025,0002,070,050274,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 02Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Sale85.6330,0002,568,90099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Sale85.6343,3333,710,605237,147May 03 08:42 PM
ROBIN HOWARD WPresident & CEOMay 01Option Exercise10.6943,334463,240280,481May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Sale83.6530,0002,509,50099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 01Sale83.6543,3343,624,889237,147May 03 08:42 PM
WHITFIELD ROY ADirectorApr 17Option Exercise14.2630,000427,800172,000Apr 18 06:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Option Exercise10.6913,881148,38882,738Apr 18 06:03 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Sale101.4613,8811,408,36668,857Apr 18 06:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Option Exercise7.215023,61980,763Apr 12 06:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Sale105.6750253,04680,261Apr 12 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Option Exercise7.2149,500356,895116,894Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Option Exercise7.219,49868,48189,759Apr 09 08:22 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Sale105.059,498997,76580,261Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Sale96.1349,5004,758,43567,394Apr 09 08:21 PM
CHESS ROBERTDirectorApr 06Option Exercise8.7925,000219,700289,223Apr 09 08:20 PM
GREER R SCOTTDirectorApr 06Option Exercise14.2630,000427,800160,333Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Option Exercise9.10110,5001,005,505177,894Apr 09 08:21 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Sale91.69110,50010,131,74567,394Apr 09 08:21 PM
GREER R SCOTTDirectorApr 06Sale92.2230,0002,766,600130,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Sale92.1425,0002,303,600274,223Apr 09 08:20 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise7.2120,000144,200100,261Apr 09 08:22 PM
Lingnau LutzDirectorApr 05Option Exercise9.2430,000277,20057,450Apr 09 08:23 PM
Lingnau LutzDirectorApr 05Sale101.7430,0003,052,20027,450Apr 09 08:23 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale101.7520,0002,035,00080,261Apr 09 08:22 PM
KUEBLER CHRISTOPHER ADirectorMar 07Option Exercise6.2437,400233,23677,900Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 07Sale97.4137,4003,643,13440,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 07Sale100.45100,14410,059,465167,513Mar 08 06:09 PM
KUEBLER CHRISTOPHER ADirectorMar 06Option Exercise5.142,60013,36443,100Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 06Sale100.302,600260,78040,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 06Sale98.29120,00011,794,800267,657Mar 08 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale82.942,545211,08268,857Feb 20 07:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale82.944,879404,664387,657Feb 20 07:09 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale82.9412,7881,060,637237,147Feb 20 07:10 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale82.942,875238,45380,261Feb 20 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale82.943,477288,38299,739Feb 20 07:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale82.942,426201,21267,394Feb 20 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerJan 31Option Exercise11.34120,0001,360,800392,536Feb 02 06:03 PM
ROBIN HOWARD WPresident & CEOJan 22Option Exercise11.3483,333944,996333,268Jan 24 06:01 PM
ROBIN HOWARD WPresident & CEOJan 22Sale75.8283,3336,318,308249,935Jan 24 06:01 PM
WINGER DENNIS LDirectorJan 04Option Exercise11.9733,750403,98877,000Jan 08 06:07 PM
KUEBLER CHRISTOPHER ADirectorJan 02Option Exercise14.2630,000427,80070,500Jan 04 06:01 PM
KUEBLER CHRISTOPHER ADirectorJan 02Sale58.6630,0001,759,80040,500Jan 04 06:01 PM
ROBIN HOWARD WPresident & CEODec 13Option Exercise11.3483,333944,996272,768Dec 15 06:00 PM
ROBIN HOWARD WPresident & CEODec 13Sale55.6983,3334,640,815189,435Dec 15 06:00 PM
Nicholson JohnSVP & Chief Operating OfficerNov 13Option Exercise9.2425,000231,000249,066Nov 15 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerNov 13Sale37.7815,910601,080233,156Nov 15 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 08Option Exercise9.53300,0002,859,000331,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 08Sale30.09300,0009,027,00031,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 07Option Exercise9.5375,409718,648106,511Nov 08 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 07Option Exercise10.6917,300184,93775,533Nov 08 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 07Sale25.7875,4091,944,04431,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 06Option Exercise9.5320,914199,31052,016Nov 08 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 06Option Exercise10.695,11754,70163,350Nov 08 06:02 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 06Sale25.075,117128,28358,233Nov 08 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 06Sale24.9820,914522,43231,102Nov 08 06:01 PM
ROBIN HOWARD WPresident & CEONov 01Option Exercise11.3483,334945,008235,838Nov 03 06:07 PM
ROBIN HOWARD WPresident & CEONov 01Sale23.5783,3341,964,182152,504Nov 03 06:07 PM
ROBIN HOWARD WPresident & CEOOct 09Option Exercise11.3483,333944,996235,837Oct 10 06:08 PM
ROBIN HOWARD WPresident & CEOOct 09Sale24.2083,3332,016,659152,504Oct 10 06:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerOct 05Option Exercise9.5343,677416,24274,779Oct 10 06:06 PM
Hora ManinderSVP Pharma Dev & Mfg OpsOct 05Option Exercise10.697,58381,06265,816Oct 10 06:07 PM
Hora ManinderSVP Pharma Dev & Mfg OpsOct 05Sale25.007,583189,57558,233Oct 10 06:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerOct 05Sale24.9743,6771,090,61531,102Oct 10 06:06 PM